Welcome to our dedicated page for Eupraxia Pharmaceuticals news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmaceuticals stock.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX; NASDAQ: EPRX) is a clinical-stage biotechnology company using its proprietary Diffusphere™ technology to develop locally delivered, extended-release drug formulations. The company focuses on creating superior treatment options for conditions with significant unmet medical needs, striving for improved patient outcomes and fewer side effects.
Eupraxia's flagship product, EP-104, is targeted at treating osteoarthritis and eosinophilic esophagitis (EoE). The company recently completed a successful Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR, aimed at alleviating knee pain due to osteoarthritis, meeting its primary endpoint and three out of four secondary endpoints. Eupraxia is also advancing EP-104GI through a Phase 1b/2a RESOLVE trial for EoE, with notable progress reported from its initial cohorts.
Recent achievements include the company's shares being approved for listing on the Nasdaq Capital Market, enhancing visibility and access to U.S. investors. Eupraxia’s financial stability is underpinned by a strong cash position, reported at $35.9 million as of March 31, 2024, which supports ongoing clinical trials and corporate activities.
The company’s innovative Diffusphere™ technology platform enables the creation of long-acting formulations for various therapeutic areas. This includes potential applications in other inflammatory joint conditions and oncology, each designed to enhance the efficacy and tolerability of current treatments.
Key partnerships, business development efforts, and strategic international expansions, such as the recent regulatory clearance in Australia and Canada to expand the RESOLVE trial, signify Eupraxia’s commitment to broadening its clinical reach and accelerating the development of its therapeutic pipeline.
For more detailed insights and updates, visit www.eupraxiapharma.com.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced its participation in the 20th International Symposium on Digestive Endoscopy (ISDE) World Congress for Esophageal Diseases in Edinburgh, Scotland, from September 22-24, 2024. The company will present a poster titled 'Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis'.
The presentation, scheduled for September 23, 2024, from 12:00 PM to 1:45 PM BST, will showcase data from cohorts one through four of the RESOLVE trial. It falls under the 'Benign Disease' theme and has been assigned paper number 265. Eupraxia, a clinical-stage biotechnology company, utilizes its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet needs.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from its RESOLVE Phase 1b/2a trial of EP-104GI for treating eosinophilic esophagitis (EoE). Key findings include:
- 10 of 11 evaluable patients in the first four cohorts experienced reduced symptom scores at 12 weeks
- The fourth cohort showed the greatest percentage change in histology scores to date
- No serious adverse events reported across all four fully-dosed cohorts
The fourth cohort data showed:
- 45% mean reduction in symptom scores at 12 weeks
- 39% mean reduction in histology composite stage scores
- 67% mean reduction in peak eosinophil counts
These results are comparable to currently approved EoE therapies. The company remains optimistic about further improvements as the trial progresses towards optimal dosing.
Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. The company's presentation is scheduled for 8:00 a.m. ET on Monday, September 9, 2024. Interested parties can view the presentation via a provided link or on the company's website.
Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release products using its proprietary DiffuSphere™ technology. The company's lead product, EP-104GI, is currently in a Phase 1b/2a trial (RESOLVE) for eosinophilic esophagitis. Eupraxia recently completed a successful Phase 2b trial (SPRINGBOARD) of EP-104IAR for osteoarthritis knee pain. The company is also developing a pipeline of long-acting formulations for inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX) reported its Q2 2024 financial results. Key highlights include:
- Positive progress in the eosinophilic esophagitis (EoE) clinical program with EP-104GI
- Presentations on EP-104IAR for knee osteoarthritis (OA) at medical meetings
- Net loss of $6.1 million, down from $9.5 million in Q2 2023
- Cash position of $23.3 million as of June 30, 2024
- New C$12 million convertible debt facility announced post-quarter end
The company anticipates reporting new data from the RESOLVE study soon and plans to engage with the FDA in Q4 2024 regarding the EP-104GI program.
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX) has announced a new C$12 million convertible debt facility with Yabema Capital and other current shareholders. The facility is available for drawdown within 120 days, subject to the release of the existing SVB Facility. The conversion price is set at C$4.84375 per Common Share.
The company has also provided an update on its existing SVB Facility, which matured on June 21, 2024, with a total liability of C$12 million. Eupraxia has fully discharged C$6 million to SVB Innovation Credit Fund and is in discussions for the remaining settlement. The company's cash reserves will be reduced by up to C$12 million to settle this debt.
Including the new convertible debt facility, Eupraxia anticipates having sufficient cash to fund operations until the second quarter of 2025.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announces that Dr. Amanda Malone, Chief Operating and Scientific Officer, will present at the Controlled Release Society 2024 Annual Meeting and Expo in Bologna, Italy, from July 8-12, 2024.
The presentation, titled 'EP-104, a novel microparticle formulation achieving extended-release of fluticasone propionate,' will occur on July 10, 2024, from 9:00 AM to 11:00 AM CEST (3:00 AM to 5:00 AM ET) during the 'Long-Acting Drug Delivery Formulations - Session #2'. The presentation can be accessed online at Eupraxia's website.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX), a clinical-stage biotech firm utilizing its proprietary DiffuSphere™ technology, announced that its CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar titled, "Exploring The Rapid Rise of Osteoarthritis." The event is set for July 9, 2024, at 8:30 am PT / 11:30 am ET. Osteoarthritis is a leading cause of disability among older adults, with knee OA affecting over 30 million people in the U.S. alone. Registration for this public event is open, and questions for Dr. Helliwell can be submitted via Tribe Public’s email or ZOOM chat during the event. John F. Heerdink, Jr. from Tribe Public will moderate the session.
Eupraxia Pharmaceuticals, a clinical-stage biotech firm, announced the results of its Annual General and Special Meeting of Shareholders held on June 6, 2024. All six board nominees were elected, with votes overwhelmingly in favor. KPMG LLP was appointed as the auditor, and several business items, including stock option plans and potential share consolidations, were approved. Eupraxia focuses on extended-release drug delivery through its DiffuSphere™ technology. The company recently completed a successful Phase 2b trial for osteoarthritis and is expanding into gastrointestinal treatments with ongoing trials.
Eupraxia Pharmaceuticals announced that it will present data from its Phase 2 SPRINGBOARD study on EP-104IAR, a treatment for knee osteoarthritis, at the EULAR European Congress of Rheumatology 2024 in Vienna, Austria. The study assesses the efficacy of a long-acting fluticasone propionate intra-articular injection compared to a vehicle placebo. The presentation, under programme number OP0274, will occur on June 14, 2024, from 10:50 AM to 11:00 AM CEST. Further details will be available on the company's website.
Eupraxia Pharmaceuticals announced the expansion of its RESOLVE Phase 1b/2a trial for EP-104GI to treat eosinophilic esophagitis (EoE). Encouraging early-phase results with eight of nine patients responding positively and exhibiting good safety profiles spurred this decision. The expansion will allow for higher doses and longer follow-up periods, now up to 52 weeks. The study will include more participants, increasing from 12-15 to 27-33. Additional clinical sites will be established to support the new recruitment targets. The trial aims to gather data to support a potential registration trial in 2025.
FAQ
What is the current stock price of Eupraxia Pharmaceuticals (EPRX)?
What is the market cap of Eupraxia Pharmaceuticals (EPRX)?
What is Eupraxia Pharmaceuticals Inc.'s core business?
What is Eupraxia’s leading product?
What recent achievements has Eupraxia made?
What are the financial highlights for Eupraxia?
What is Diffusphere™ technology?
What therapeutic areas does Eupraxia target?
What is the status of the RESOLVE trial?
How is Eupraxia expanding its clinical reach?
What is the SPRINGBOARD trial?
Where can I find more information about Eupraxia?
